The pharmaceutical company Double Bond Pharma reported a small revenue during the first quarter compared with none in the same period the previous year. Operating loss decreased slightly.Revenue amounted to SEK 0.1 million (0).Operating profit was SEK -0.3 million (-0.4). Profit after tax was SEK -0.3 million (-1.1), and per share SEK 0.00 (-0.01). Cash and cash equivalents amounted to SEK 0.9 million (2.4)."We have a clear order of priorities where the focus is on signing licensing agreements with one of the prioritized partners we are in discussions with. At present, we are holding four parallel discussions. Our second priority is to secure our rights to the other products in the portfolio so that, in the long term, we can work more actively on developing them," comments CEO Igor Lokot.Double Bond Pharma, SEK millionQ1-2026Q1-2025ChangeNet sales0.10Operating profit-0.3-0.4Net profit-0.3-1.1Earnings per share, SEK0.00-0.01Cash and cash equivalents0.92.4-62.5%